All news

Ardelyx faces securities fraud class action over drug access claims

Alpha Vantage · Business Wire · · AI-summarised by FinFlash

Schall, Brown & Schwartz LLP filed a securities fraud class action against Ardelyx (NASDAQ: ARDX), covering January 13, 2025 to August 6, 2026. The suit alleges misleading statements about reimbursement barriers affecting patient access to XPHOZAH and IBSRELA, which hurt commercial performance. Shareholders have until November 16, 2026 to seek lead plaintiff status.

Read original source

ARDX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.